Blood cancer is a type of cancer with a fast and complicated progression. After treatment, if not closely monitored, the possibility of recurrence and unpredictable progression can lead to danger to the patient. That places a great need for minimal residual (MRD) monitoring after blood cancer treatment to predict the likelihood of recurrence.
Dario C. (2010) showed that the number of residual blood cancer cells is closely related to the possibility of cancer recurrence.
MRD > 1%: Poor treatment outcome, recurrence is certain
0.1% < MRD < 1%: Up to 75% chance of recurrence
MRD < 0.01%: Treatment is effective (1)
CtDNA is DNA that is unique to cancer cells, which allows us to assess the therapeutic effect of therapy. The absence of ctDNA indicates the possibility of successful treatment and vice versa (2).
With a solution of 523 oncogenes of 9 common cancers, Illumina’s NGS-based ctDNA monitoring offers the potential for successful diagnosis and treatment or metastasis and transformation of related cancers.
The immune system is closely related to cancer treatment. The increase or decrease in the number of cancer cells shows how responsive the body is to cancer therapy (3).
Biomedic provides a comprehensive solution from equipment to chemicals.
Kits:
Machine system:
The solution to evaluate all immune cells on the basis of Flow Cytometer technology with the DxFLEX system and the DuraClone breakthrough dry gel antibody kit offers outstanding advantages.